ALIVE Israel HealthTech Fund

What ALIVE Israel HealthTech Fund does

ALIVE Israel HealthTech Fund is an Israel-focused venture capital fund manager investing in mid-to-late stage HealthTech companies, primarily medical devices and digital health. Founded operationally in 2020 (publicly introduced in January 2019) and headquartered in Savyon, Israel, the firm is led by four co-founders — Prof. Ari Shamiss, Prof. Rafael Beyar, Michel Habib, and Dudi Klein — whose combined clinical, healthcare-system, and venture operating backgrounds underpin a stated edge in assessing clinical viability, regulatory pathways, and US market relevance. The manager operates three fund vehicles to date: Fund I (Alive One, a 2020 vintage with more than $110M AUM and a 12-company portfolio), Fund II (Alive Next), and ALIVE Growth Fund III, which announced its initial closing at $180-200M in November 2025 to back growth-stage Israeli and international medical device and digital health companies.

ALIVE's portfolio spans cardiovascular and structural heart devices (Innovalve, Append, Magenta Medical), urology and ophthalmology medical devices (Vessi Medical, Beyonics Vision, Beyonics Surgical), and digital health platforms including AI-driven primary care (Navina), proteomics AI for oncology (OncoHost), healthcare IoT security (Cynerio), medication management (Medisafe), femtech (Nevia), and social/mental health (Wisdo Health). The fund actively partners with international VCs, leading crossover funds and global corporations for co-investment and exit pathways, with notable realized exits including Innovalve to Edwards Lifesciences (~$350M, July 2024), Cynerio to Axonius ($100M+, July 2025), and Wisdo Health to Talkspace (July 2025).

ALIVE generates revenue through traditional venture fund economics — management fees on committed/invested AUM and carried interest on profitable exits. Fund management fees, LP relationships, and exit timing are not publicly disclosed, and the firm is privately held with no parent company. Go-to-market is direct: deal sourcing through the founding partners' clinical and industry networks, syndication with tier-one healthcare-focused institutional investors, and active board participation across portfolio companies. The fund positions itself as an active operating partner, centering its approach on measurable clinical and commercial outcomes rather than purely financial oversight.

Name

ALIVE Israel HealthTech Fund

Legal name

Alive

Website

https://alivevc.com/

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

ALIVE Israel HealthTech Fund is an Israel-focused venture capital manager investing in mid-to-late stage medical device and digital health companies. Founded in 2020 and led by four co-founders with clinical and healthcare-system backgrounds, it operates three fund vehicles serving HealthTech founders targeting the US and global markets.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Funds, Trusts, and Other Financial Vehicles (525)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

akta.pro secondary industry

SDG / Thematic Sustainable Investment Funds (FSANAJAN)

Keywords

• Venture capital fund
• Healthtech investments
• Medical device financing
• Digital health investing
• Growth stage capital

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Distribution channels2 records

Marketing channels6 records

Core offering

ALIVE Israel HealthTech Fund is a mid-to-late stage HealthTech venture capital fund that invests in Israeli and international medical device and digital health companies through three fund vehicles: ALIVE One, ALIVE Next, and ALIVE Growth Fund III. The fund provides active board participation, clinical and regulatory expertise, and US healthcare market knowledge to portfolio companies. Its 12-company portfolio spans cardiovascular devices, orthopedics, ophthalmology, urology, femtech, AI-driven clinical intelligence, medication management, healthcare cybersecurity, oncology proteomics, and mental health platforms.

Product overview

ALIVE Israel HealthTech Fund is a HealthTech investment fund, not a product company. The fund operates three investment vehicles (ALIVE One, ALIVE Next, and ALIVE Growth) that invest in Israeli and international medical device and digital health companies. The fund's portfolio consists of 12 companies across medical devices (Innovalve, Append, Magenta Medical, Vessi Medical, Beyonics Vision, Beyonics Surgical) and digital health (Medisafe, Nevia, Cynerio, Wisdo Health, Navina, Oncohost). Several portfolio companies have been acquired including Innovalve (by Edwards Lifesciences), Medisafe, Cynerio (by Axonius), Navina, Wisdo Health (by Talkspace), Nevia, Vessi Medical, and Oncohost.

Differentiator

Problem solved

Functional benefit

Products and services

• ALIVE One Fund ALIVE's inaugural HealthTech venture capital fund vehicle (2020 vintage) with more than $110M AUM, investing in a portfolio of 12 Israeli and international mid-to-late stage Medical Device and Digital Health companies through direct equity investment and active board participation. Targeted at limited partners seeking HealthTech exposure.
• ALIVE Growth Fund III ALIVE's growth-stage HealthTech venture capital fund (announced initial closing November 2025) targeting $180-200M, investing in Israeli and international mid-to-late stage Medical Device and Digital Health companies. Partners with international VCs, leading crossover funds, and global corporations to drive rapid expansion and value creation for portfolio companies.

Quantifiable outcome

• Multiple successful exits including Innovalve ($350M to Edwards Lifesciences), Cynerio ($100M+ to Axonius)

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• OrbiMed: OrbiMed is one of the world's largest healthcare-dedicated investment firms, investing across medical devices, digital health, and biopharma at all stages. It is a direct peer to ALIVE in Israeli mid-to-late stage HealthTech — OrbiMed has co-led rounds with ALIVE in Magenta Medical — and competes for the same founders and LPs at scale.
• aMoon Fund: aMoon is an Israel-based healthcare and life sciences venture fund investing across digital health, medical devices, and biopharma. It is the closest direct competitor to ALIVE in the Israeli HealthTech mid-to-late stage segment, sharing the same founder base, clinical-network dynamics, and LP ecosystem.
• Accelmed: Accelmed is an Israel-based medical-device focused venture capital firm investing in growth-stage and commercial-stage device companies. It directly overlaps with ALIVE's medical-device portfolio thesis (e.g., structural heart, surgical devices) and competes for the same Israeli medtech deal flow.
• Peregrine Ventures: Peregrine Ventures is an Israeli venture capital firm with a strong medical-device franchise. It is a direct peer in Israeli growth-stage medical device investing, competing for similar assets and clinical partnerships as ALIVE.
• Triventures: TriVentures is an Israel- and US-based medtech and digital health venture capital fund. It directly competes with ALIVE in early-to-growth stage Israeli medical devices and digital health, sharing similar investor ecosystems.
• Pitango Venture Capital: Pitango is one of Israel's largest venture capital firms with dedicated healthtech investment activity. It is a direct competitor for Israeli mid-to-late stage healthcare deals and a potential co-investor alongside ALIVE.

Broad incumbents

• Longitude Capital: Longitude Capital is a US-based healthcare-dedicated growth equity and venture firm investing across medical devices, digital health, and life sciences. It is a broader incumbent peer that competes for crossover HealthTech rounds and shares the late-stage clinical-validation thesis ALIVE applies.
• Vivo Capital: Vivo Capital is a US- and Asia-based healthcare-focused investment firm investing across venture, growth, and public equities in healthcare. It is a broader incumbent peer overlapping with ALIVE's growth-stage medical-device and digital-health investment universe.
• New Enterprise Associates (NEA) — Healthcare: NEA is a large US venture firm with a long-standing dedicated healthcare practice covering medical devices and digital health. It is a broader incumbent peer that competes for late-stage HealthTech rounds and co-invests alongside specialist Israel-focused funds like ALIVE.
• Insight Partners — Healthcare: Insight Partners is a large global growth-equity investor with an active healthcare practice spanning digital health and healthtech software. It is a broader incumbent peer that competes with ALIVE for later-stage, larger-check HealthTech rounds in Israel and globally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alive-healthtech-fund

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments15 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALIVE Israel HealthTech Fund